Background: Cancer vaccines, including those targeting cancer/testis antigens (CTA) such as MAGE-A3, are able to induce measurable adaptive immune responses, but have largely failed to demonstrate clinical benefit in phase III studies of solid tumors. The gene discussed is MAGEA3; the disease is cancer.